PORTFOLIO

We are seeking to build a diversified portfolio of more than 20 molecules across multiple therapeutic areas and modalities.

 
portfolio.jpg
 

 

Since 2016, we have acquired and are rapidly advancing several high-value candidates from IND-enabling through Phase 2.

 
 
bp-pipeline_01.png
bp-pipeline-footnotes.png
 

 

BOS161721

BOS161721 is a humanized monoclonal antibody that targets Interleukin-21, a key component in the adaptive immune response, and may play a key role in autoimmune diseases such as lupus among others. Boston Pharmaceuticals is currently enrolling patients with systemic lupus erythematosus in a Phase 1b multiple ascending dose trial. This program originated with Medimmune, the global biologics research and development arm of AstraZeneca, and was Boston Pharmaceuticals’ first acquisition. 
RETURN TO PIPELINE

 

 

BOS172767

BOS172767 is an inverse agonist targeting retinoic acid-related orphan nuclear receptor gamma-t (ROR-γt). ROR-γt is the key transcription factor and the master regulator of human Th17 cells, which play an important role in the pathogenesis of a diverse group of immune-mediated diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, ankylosing spondylitis and asthma. BOS172767 has been dosed in healthy volunteers in a Phase 1 trial.
RETURN TO PIPELINE

 

 

BOS173717

BOS173717 is a sphingosine 1-phosphate 1 (S1P1) receptor modulator. S1P1 is a validated target for the potential treatment of autoimmune indications. BOS173717 has previously completed Phase 1 trials in patients.
RETURN TO PIPELINE

 

BOS172722

BOS172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with potential for the treatment of various forms of breast cancer. Boston Pharmaceuticals is currently enrolling patients in an ongoing Phase 1 trial for the potential treatment of triple negative breast cancer. BOS172722 was acquired from CRT Pioneer Fund LP (managed by Sixth Element Capital) and was discovered at the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London. The research was originally supported by Cancer Research UK and Breast Cancer Now.
RETURN TO PIPELINE

 

 

BOS172738

BOS172738 is a highly selective and potent RET (ret proto-oncogene) kinase inhibitor. RET rearrangements and activating mutations are associated with several types of cancers, including non-small cell lung, colorectal and thyroid. BOS172738 is currently in IND-enabling studies. This program was originated at Daiichi Sankyo Pharmaceuticals and is being jointly developed by the two companies.
RETURN TO PIPELINE

 

 

BOS1728515

BOS1728515 is a small molecule selective potassium channel blocker in late preclinical development for the treatment of atrial fibrillation (AF). Boston Pharmaceuticals licensed worldwide exclusive rights for the development, manufacturing and commercialization of BOS1728515 (formerly F17727) from Pierre Fabre Pharmaceuticals.
RETURN TO PIPELINE

 

BOS162262

BOS162262 is a small molecule with a unique mechanism to inhibit metallo beta lactamase producing bacteria, including New Delhi metallo strains. BOS162262 is currently in IND-enabling studies.
RETURN TO PIPELINE

 
 

Learn more about how to partner with us.